Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

7.950 +0.040 (+0.51%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist

Price and Volume

Volume	608,591
Open	7.900
Bid (Size)	7.850 (100)
Ask (Size)	8.130 (2,900)
Prev. Close	7.910
Today's Range	7.890 - 8.180
52wk Range	1.780 - 13.67
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Today 8:00 EST

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

February 03, 2026

Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of...

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-9.4%	-9.4%
1 Month	-10.5%	-10.5%
3 Month	+6.1%	+6.1%
6 Month	+108.7%	+108.7%
1 Year	+174.1%	+174.1%

More News

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

January 12, 2026

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

January 05, 2026

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

December 18, 2025

Via Chartmill

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

December 17, 2025

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 17, 2025

Via Chartmill

These stocks are gapping in today's session ↗

December 17, 2025

Via Chartmill

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

December 17, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

What's going on in today's pre-market session ↗

December 17, 2025

Via Chartmill

Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity ↗

December 15, 2025

Via The Motley Fool

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

December 15, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Which stocks are moving on Monday? ↗

December 15, 2025

Via Chartmill

ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy

December 15, 2025

Via AB Newswire

Monday's session: top gainers and losers ↗

December 15, 2025

Via Chartmill

Which stocks are gapping on Monday? ↗

December 15, 2025

Via Chartmill

KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? ↗

December 15, 2025

Via Stocktwits

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

December 15, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

December 14, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 20, 2025

Via Benzinga

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 12, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

November 10, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

Via Benzinga

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

November 03, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

October 29, 2025

From Kyverna Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?

Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?

Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?

The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market

What is the current price of Kyverna Therapeutics, Inc. - Common Stock?

The current price of Kyverna Therapeutics, Inc. - Common Stock is 7.950

When was Kyverna Therapeutics, Inc. - Common Stock last traded?

The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 02/24/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.